SecBot SecBot
425 ·Filed Sep 30, 2026

LAB

STANDARD BIOTOOLS INC.
BULLISH
Impact 6/10
Horizonweeks Processed1mo ago SEC0001140361-26-038111
Rule 425 M&A communications
Actionable Insight ▲ Bullish

Monitor the proxy statement filing for the stockholder vote on both the Element sale and the Treeline merger. The improved cash position strengthens the pro-forma balance sheet for the combined entity post-merger.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+20
Entry
$0.7283
T+0 close · Sep 30, 2026 · via day close
Latest settled
−14.87%
T+20 · $0.6200 · next T+60 in 6w
Vs SPY
−15.57%
α at T+20
Latest observation
+2.36%
T+31 · FF3 residual α
  1. T+0 · Oct 1 $0.7283entry
  2. T+1 · 7w ago +2.25%α +1.51% · $0.7447
  3. T+5 · 6w ago −7.96%α −9.26% · $0.6703
  4. T+20 · 19d ago −14.87%α −15.57% · $0.6200
  5. T+32 · todayOpen
  6. T+60 · in 6w Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Standard BioTools terminated its prior agreement to sell its mass cytometry business to Multiplex Bio and entered into a new $5.5 million cash deal with Element Biosystems (GMT Venture), which the board deemed a superior proposal. The new deal eliminates a $10 million working capital loan obligation, improving net cash by ~$15 million for the pending Treeline merger. The transaction requires stockholder approval and is expected to close by end of 2026 concurrently with the Treeline merger.

Key Financial Metrics

Deal Value
$5.5M
Deal Type
acquisition

Key Facts

  • Standard BioTools terminated the Multiplex Bio purchase agreement and entered a new agreement with Element Biosystems (GMT Venture) for $5.5 million cash.
  • The new deal eliminates a $10 million working capital loan that was required under the Multiplex Bio agreement.
  • Net cash position for the Treeline merger exchange ratio calculation improves by approximately $15 million versus the Multiplex Bio deal.
  • GMT Venture paid $1.0 million of the $1.5 million Multiplex Bio termination fee on Standard BioTools' behalf.
  • The Element transaction is subject to stockholder approval and concurrent closing of the Treeline merger.
  • Outside date for the Element deal is June 30, 2027, with two automatic three-month extensions possible.

Financial Impact

Upfront cash proceeds of $5.5 million; net cash improvement of ~$15 million for the Treeline merger exchange ratio calculation after accounting for termination and transaction fees.

cashnet cash positionmerger exchange ratio

Risk Factors

  • Stockholder approval for the Element transaction may not be obtained.
  • The Treeline merger may not close, which is a condition to the Element deal.
  • A competing superior proposal for the mass cytometry business could emerge before the stockholder vote.
  • The deal could be terminated if not closed by June 30, 2027, triggering a $1.0 million termination fee.

Investment Themes

Industrials & Manufacturing

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
425 Filing (Primary)0001140361-26-038111
Document: 0001140361-26-038111-index-headers.html0001140361-26-038111
Document: 0001140361-26-038111-index.html0001140361-26-038111
Document: 0001140361-26-038111.txt0001140361-26-038111

Track record

23 reports on LAB

Performance horizon

6 of 8 bullish or bearish reports moved the stock their way by T+1. Best: +17.95% at T+20 after the Feb 24, 2026 report. 8 of 8 went positive at some point.

Filters
  1. Nov 16, 2026today 425 Neutral 4/10 Entry price pending
  2. Nov 16, 2026today 8-K Neutral 3/10 Entry price pending
  3. Nov 3, 202613d ago 425 Neutral 3/10 Entry $0.6108 to $0.6160 Now $0.6200 +1.51% ▲ +0.85% −0.80% vs SPY
  4. Nov 3, 202613d ago 8-K Neutral 4/10 Entry $0.6108 to $0.6160 Now $0.6200 +1.51% ▲ +0.85% −0.80% vs SPY
  5. Nov 3, 202613d ago Press Release Neutral 3/10 Entry $0.6108 to $0.6160 Now $0.6200 +1.51% ▲ +0.85% −0.80% vs SPY
  6. Oct 22, 202626d ago EFFECT Neutral 4/10 Entry $0.6400 to $0.6056 Now $0.6200 −3.12% ▼ −5.38% −4.85% vs SPY
  7. Oct 21, 202626d ago S-4/A Bearish 7/10 Entry $0.6500 to $0.6400 Now $0.6200 +4.62% ▲ +1.54% +0.36% vs SPY
  8. Oct 9, 20265w ago S-4/A Neutral 6/10 Entry $0.6578 to $0.6589 Now $0.6200 −5.75% ▲ +0.17% +0.18% vs SPY
  9. Oct 5, 20266w ago 425 Neutral 5/10 Entry $0.7220 to $0.6787 Now $0.6200 −14.13% ▼ −6.00% −5.76% vs SPY
  10. Oct 5, 20266w ago 8-K Neutral 4/10 Entry $0.7220 to $0.6787 Now $0.6200 −14.13% ▼ −6.00% −5.76% vs SPY
Showing 10 of 23

US Market Status

Market Closed · Opens Wed (9h 49m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 30, 2026